Education
About Us
Working with TipRanks
Follow Us
Quoin Pharmaceuticals (QNRX)
NASDAQ:QNRX
QNRX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$5.01 - $54.95
Previous CloseN/A
Volume155.80K
Average Volume (3M)237.68K
Market Cap
$1.53M
Enterprise Value-$9.81M
Total Cash (Recent Filing)$3.62B
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta-0.03
Next Earnings
May 07, 2025EPS Estimate
-7.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-81.73
Shares Outstanding588,167
10 Day Avg. Volume73,224
30 Day Avg. Volume237,676
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.70
P/FCF Ratio0.00
Enterprise Value/Market Cap-6.39
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda1.04
Forecast
1Y Price Target
$2.00Price Target Upside-69.51% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
Bulls Say, Bears Say
Bulls Say
EfficacyAdditional positive data shows significant improvement in patients treated twice daily with QRX003, supporting its efficacy in treating Netherton Syndrome.
Market PotentialAn approved therapy for Netherton Syndrome has significant market potential as it remains a very difficult to treat disease with no approved disease-modifying therapeutic options.
Safety ProfileThe absence of new safety concerns despite increased dosing of QRX003 positively supports its safety profile.
Bears Say
Chronic Therapy RequirementDiscontinuation of QRX003 treatment reverses the treatment benefit, suggesting potential chronic use may be required for patients to maintain symptom relief.
Durability ConcernsUpdated data showed that 4 weeks post-discontinuation of therapy, the patients’ symptom and disease severity scores returned essentially to baseline levels.
Symptom Relief DurabilityThe shares are trading down approximately 25% as some investors may be concerned that QRX003 did not maintain symptom relief durability or 'cure' patients.
---
Ownership Overview
17.79% Insiders
―
Mutual Funds
15.24% Other Institutional Investors
66.96% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
QNRX FAQ
What was Quoin Pharmaceuticals’s price range in the past 12 months?
Quoin Pharmaceuticals lowest stock price was $5.01 and its highest was $54.95 in the past 12 months.
What is Quoin Pharmaceuticals’s market cap?
Quoin Pharmaceuticals’s market cap is $1.53M.
When is Quoin Pharmaceuticals’s upcoming earnings report date?
Quoin Pharmaceuticals’s upcoming earnings report date is May 07, 2025 which is in 13 days.
How were Quoin Pharmaceuticals’s earnings last quarter?
Quoin Pharmaceuticals released its earnings results on Mar 13, 2025. The company reported -$12.25 earnings per share for the quarter, beating the consensus estimate of -$16.1 by $3.85.
Is Quoin Pharmaceuticals overvalued?
According to Wall Street analysts Quoin Pharmaceuticals’s price is currently Overvalued.
Does Quoin Pharmaceuticals pay dividends?
Quoin Pharmaceuticals does not currently pay dividends.
What is Quoin Pharmaceuticals’s EPS estimate?
Quoin Pharmaceuticals’s EPS estimate is -7.18.
How many shares outstanding does Quoin Pharmaceuticals have?
Quoin Pharmaceuticals has 588,167 shares outstanding.
What happened to Quoin Pharmaceuticals’s price movement after its last earnings report?
Quoin Pharmaceuticals reported an EPS of -$12.25 in its last earnings report, beating expectations of -$16.1. Following the earnings report the stock price went down -0.674%.
Which hedge fund is a major shareholder of Quoin Pharmaceuticals?
Currently, no hedge funds are holding shares in QNRX
---
Company Description
Quoin Pharmaceuticals
Quoin Pharmaceuticals, Ltd., a specialty pharmaceutical company, focuses on the development of therapeutic products for rare and orphan diseases. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome. It also develops QRX004 for the treatment dystrophic epidermolysis bullosa; and QRX006, a therapy to treat rare skin disease. The company is based in Ashburn, Virginia.
---
QNRX Stock 12 Month Forecast
Average Price Target
$2.00
▼(-69.51% Downside)
Technical Analysis
Palisade Bio
―
Galmed Pharmaceuticals
―
InMed Pharmaceuticals
―
Artelo Biosciences
―
Galecto
―
Best Analysts Covering QNRX
1 Year
1 Year Success Rate
0/20 ratings generated profit
1 Year Average Return
-79.92%
reiterated a buy rating last month
Copying Naz Rahman's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -79.92% per trade.
---